Format

Send to

Choose Destination
Am J Transl Res. 2016 Jul 15;8(7):2969-80. eCollection 2016.

Wallichinine reverses ABCB1-mediated cancer multidrug resistance.

Author information

1
Institute of Materia Medica, Zhejiang Chinese Medical University Hangzhou, Zhejiang, China.
2
Department of Cell Biology & Institute of Biomedicine, National Engineering Research Center of Genetic Medicine, Guangdong Provincial Key Laboratory of Bioengineering Medicine, College of Life Science and Technology, Jinan University Guangzhou, Guangdong, China.
3
Chemical Biology Center, Lishui Institute of Agricultural Sciences Lishui, Zhejiang, China.

Abstract

Overexpression of ABCB1 in cancer cells is one of the main reasons of cancer multidrug resistance (MDR). Wallichinine is a compound isolated from piper wallichii and works as an antagonist of platelet activiating factor receptor to inhibit the gathering of blood platelet. In this study, we investigate the effect of wallichinine on cancer MDR mediated by ABCB1 transporter. Wallichinine significantly potentiates the effects of two ABCB1 substrates vincristine and doxorubicin on inhibition of growth, arrest of cell cycle and induction of apoptosis in ABCB1 overexpressing cancer cells. Furthermore, wallichinine do not alter the sensitivity of non-ABCB1 substrate cisplatin. Mechanistically, wallichinine blocks the drug-efflux activity of ABCB1 to increase the intracellular accumulation of rhodamine 123 and doxorubicin and stimulates the ATPase of ABCB1 without alteration of the expression of ABCB1. The predicted binding mode shows the hydrophobic interactions of wallichinine within the large drug binding cavity of ABCB1. At all, our study of the interaction of wallichinine with ABCB1 presented herein provides valuable clues for the development of novel MDR reversal reagents from natural products.

KEYWORDS:

ABCB1; Wallichinine; cancer; multidrug resistance

PMID:
27508017
PMCID:
PMC4969433

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center